Bracanat contains the active substance Olaparib. It is an oral targeted therapy used in the treatment of certain types of cancers. This medication belongs to a class of drugs known as PARP inhibitors. Bracanat is primarily used in patients with specific inherited genetic mutations, such as BRCA1 or BRCA2, which are associated with higher risks of developing cancers like breast, ovarian, pancreatic, and prostate cancer. It is usually prescribed when the disease has advanced or returned after previous treatments.

Mechanism of Action
Olaparib works by inhibiting the enzyme called poly ADP-ribose polymerase, commonly known as PARP. PARP plays a vital role in repairing damaged DNA in cells. Cancer cells with BRCA mutations already have compromised DNA repair mechanisms. By blocking PARP, Olaparib prevents the cancer cells from repairing their DNA, leading to the accumulation of damage. This causes the cancer cells to die, while healthy cells with intact repair systems remain less affected. This selective mechanism makes Olaparib an effective therapy for patients with specific genetic vulnerabilities in their cancer.

Uses
Bracanat is used in the treatment of the following conditions:

• Ovarian cancer, especially in patients with BRCA mutations who have responded well to platinum-based chemotherapy

• Breast cancer in patients with a confirmed BRCA mutation

• Metastatic pancreatic cancer with a germline BRCA mutation

• Metastatic castration-resistant prostate cancer with BRCA mutations or similar genetic alterations

  Adverse Effects
  Like all medications, Bracanat may cause side effects, although not everyone experiences them. Common side effects include tiredness or fatigue, nausea, vomiting, and a decrease in appetite. Some patients may experience anemia or other changes in their blood counts, including a drop in white blood cells or platelets. Headache, dizziness, and indigestion may also occur.

  More serious but less common side effects include the risk of developing blood disorders such as myelodysplastic syndrome or acute myeloid leukemia, especially in patients who have received previous cancer treatments. Regular monitoring through blood tests is recommended during therapy.

  Patients are advised to inform their healthcare providers if they experience unusual bruising, prolonged infections, persistent fatigue, or any signs of allergic reactions during the course of treatment.